IP Group
IP Group is a London-based corporate firm that provides financial, strategic, and commercial expertise to clients internationally. Founded in 2001, the company focuses on creating value through the commercialisation of intellectual property derived from research-intensive institutions. It manages the end-to-end process of identifying viable IP, developing or partnering to build value, and establishing commercial arrangements that translate scientific advances into practical products and businesses. IP Group combines industry insight and financial experience to support science- and technology-based ventures, offering capital as well as strategic guidance to help companies grow and accelerate the impact of research. Its work spans clean technology, life sciences, and other deep technology sectors, with a track record of backing and developing ventures that aim to deliver tangible societal and economic outcomes.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Health Care
Enterprise Therapeutics
Series B in 2024
Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.
Crescendo Biologics
Venture Round in 2023
Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.
Pulmocide
Series C in 2022
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.
GripAble
Series A in 2022
GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.
Aptatek Biosciences
Seed Round in 2022
Aptatek Biosciences develops portable medical devices for managing inborn diseases. Its flagship product monitors phenylalanine levels in real-time for individuals with Phenylketonuria (PKU), enabling immediate dietary adjustments and improved patient compliance.
Pulmocide
Series C in 2021
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.
Kira Biotech
Series A in 2019
Founded in 2017, Kira Biotech is an Australian biotechnology company dedicated to developing novel immunomodulatory compounds. Its lead candidate, KB312, is a first-in-class monoclonal antibody targeting activated immune cells to induce immune tolerance and treat immune system disorders such as rheumatoid arthritis and systemic lupus erythematosus.
Crescendo Biologics
Series B in 2018
Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.
Enterprise Therapeutics
Series B in 2018
Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.
Akamis Bio
Venture Round in 2017
Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.
Azellon Cell Therapeutics
Venture Round in 2015
Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.
Azellon Cell Therapeutics
Venture Round in 2011
Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.
Azellon Cell Therapeutics
Seed Round in 2009
Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.
ACSIAN
Seed Round in 2005
ACSIAN is a group of nutritionists who collaborate with pediatricians, gastroenterologists, psychologists, psychiatrists, dieticians, and researchers. ACSIAN conducts and participates in food intolerance research in partnership with the CNR and the University of Pisa, and it promotes programs in diverse geographical realities through its members to combat childhood obesity and avoid metabolic disorders associated with it.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.